Notably, the emergence of immune checkpoint (ICP) blockade proteins as promising candidates for cancer immunotherapy prompted us to conduct a meticulous evaluation of the intricate interplay between GLIPR2 expression levels and the expressions of ICP genes across various malignancies. Here, GLIPR2 is linked to cancer.